Jean-Frédéric B.
- Country
- France
- Department
- Digestive Oncology Department
Research Overview
- Phase 1/2 Study of Pumitamig Monotherapy or in Combination with Ipilimumab for First-Line Advanced or Unresectable Hepatocellular Carcinoma
- Phase III Randomized Open‑Label Study of Atezolizumab + Lenvatinib or Sorafenib vs Lenvatinib/Sorafenib Alone in Previously Treated Unresectable HCC
- Phase 3 Randomized Study of INCB161734 Plus Combination Chemotherapy Versus Placebo Plus Chemotherapy in KRAS G12D‑Mutated Metastatic Pancreatic Ductal Adenocarcinoma
Data & Insights
Has run more than one trial at 195 of 367 partner sites.
Specializations
Hepatocellular Carcinoma Management
Specializes in innovative therapeutic approaches for hepatocellular carcinoma (HCC), particularly focusing on combinations of local and systemic treatments.
- Percutaneous ablation procedures
- Transarterial chemoembolization (TACE)
- Immunotherapy combinations
Investigates advanced treatment modalities for both early-stage and advanced HCC, incorporating targeted therapies and immunotherapeutic agents.
Biliary Tract Cancer Research
Focuses on developing treatment strategies for biliary tract cancers, including cholangiocarcinoma and advanced biliary malignancies.
- Novel systemic therapies
- Personalized medicine approaches
- Combination immunotherapy protocols
Explores innovative therapeutic combinations for both localized and metastatic disease presentations.
Pancreatic Cancer Treatment
Conducts research in pancreatic adenocarcinoma treatment, with particular emphasis on advanced and metastatic disease.
- First-line treatment strategies
- Targeted therapeutic approaches
- Adjuvant therapy protocols
Investigates novel therapeutic combinations and targeted treatments for improved patient outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.